Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable" style="float:right; margin-right: 5px;" |- |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align=...")
 
m
Line 1: Line 1:
 +
{| class="wikitable" style="text-align:center; width:50%;"
 +
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
 +
|-
 +
| style="background-color:#F0F0F0; width:15%" |[[File:MartinSchoen.jpg|frameless|upright=0.3|center]]
 +
| style="width:35%" |<big>[[User:Marteens|Martin W. Schoen, MD, MPH]]<br>Saint Louis University<br>St. Louis, MO</big>
 +
|-
 +
|}
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-

Revision as of 19:10, 27 April 2019

Section editor
MartinSchoen.jpg
 Martin W. Schoen, MD, MPH
Saint Louis University
St. Louis, MO
1 regimens on this page
1 variants on this page


All lines of therapy

Tagraxofusp monotherapy

back to top

Regimen

Study Evidence
Frankel et al. 2014 Phase I/II, <20 pts

Chemotherapy

21-day cycles

References

  1. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Blastic_plasmacytoid_dendritic_cell_neoplasm&oldid=36660"